Merus N.V.

NASDAQ:MRUS

50 (USD) • At close September 6, 2024
Bedrijfsnaam Merus N.V.
Symbool MRUS
Munteenheid USD
Prijs 50
Beurswaarde 3,410,525,000
Dividendpercentage 0%
52-weken bereik 19.805 - 61.61
Industrie Biotechnology
Sector Healthcare
CEO Dr. Sven Ante Lundberg M.D.
Website https://www.merus.nl

An error occurred while fetching data.

Over Merus N.V.

Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase 1/2

Vergelijkbare Aandelen

Verve Therapeutics, Inc. logo

Verve Therapeutics, Inc.

VERV

5.595 USD

Nektar Therapeutics logo

Nektar Therapeutics

NKTR

1.12 USD

Codexis, Inc. logo

Codexis, Inc.

CDXS

2.74 USD

Avidity Biosciences, Inc. logo

Avidity Biosciences, Inc.

RNA

40.46 USD

Evolus, Inc. logo

Evolus, Inc.

EOLS

14.71 USD

Rocket Pharmaceuticals, Inc. logo

Rocket Pharmaceuticals, Inc.

RCKT

18.51 USD

The Oncology Institute, Inc. logo

The Oncology Institute, Inc.

TOI

0.3 USD

HealthStream, Inc. logo

HealthStream, Inc.

HSTM

28.34 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)